CTOs on the Move

Cue Health

www.cuehealth.com

 
Cue Health is a health technology company that develops and manufactures portable, compact, connected medical diagnostic products that help people, organizations, and communities protect human health. Headquartered in San Diego, California, our mission is to empower healthcare providers and organizations by increasing their access to rapid, accurate, actionable health data in real-time. We have built a culture that is dynamic, innovative, and results-oriented. We seek driven and talented individuals to join our multi-disciplinary engineering, regulatory, clinical, operations, production, and testing teams. If you`re ready to help us reinvent the future of healthcare, reach out to us today.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.cuehealth.com
  • 4980 Carroll Canyon Road Suite 100
    San Diego, CA USA 92121
  • Phone: 858.412.8151

Executives

Name Title Contact Details
Vimal Subramanian
Chief Information Security Officer Profile
Vimal Subramanian
Head of Information Security and Privacy Profile

Funding

Cue Health raised $13M on 04/01/2020
Cue Health raised $100M on 06/10/2020
Cue Health raised $481M on 10/14/2020
Cue Health raised $235M on 05/13/2021

Similar Companies

Medallion Laboratories

Medallion Laboratories is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovate Biopharmaceuticals

Innovate is a clinical stage biotechnology company developing novel medicines for gastroenterological disorders.

Cortendo AB

Cortendo AB is a global biopharmaceutical company founded in 1996, incorporated in Sweden, and based in the United States. Cortendo recognizes the urgent need to make new medicines available for people with orphan diseases, and the Company is committed to delivering therapies that make a difference. An orphan disease is one for which the pharmaceutical industry has not worked to make new medicines. It may be a rare disease (in the U.S. this is defined as a disease that affects fewer than 200,000 people) or a disease such as tuberculosis, cholera, typhoid or malaria that is not often diagnosed in developed countries but remains common in countries that are still developing. Cortendo’s initial strategic goal is to be the global leader in finding, developing and making medicines for people with orphan endocrine diseases, with its most advanced program in Cushing’s syndrome. Cortendo research led to the development of COR-003 (levoketoconazole) which is currently being studied in the Phase 3 global SONICS trial for the treatment of endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Cortendo is building the capabilities and resources to independently develop and commercialize its orphan assets in key global markets and to partner non-strategic product opportunities, such as BioPancreate-2001 for Type 1 and Type 2 diabetes. The company also intends to leverage its commercial expertise by working with partners to acquire, develop, and commercialize late-stage or commercial assets in a select few orphan disease focus areas.  

Argenx

The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.

NextBio

NextBio is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.